Pediatric Dermatology News

Healio has compiled March’s most-read news in dermatology.

SAN DIEGO — Researchers found that children with moderate to severe atopic dermatitis have a higher mean weight and BMI, but a lower mean height, than healthy children, according to a poster presented here.

Ectodermal dysplasia, a condition associated with impaired quality of life, increased mortality and increased morbidity, may have a lower prevalence than previously reported, according to a study.

SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel achieved faster-acting efficacy than dyads and vehicle, according to a study.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

The FDA has approved an expanded indication for Spevigo injection to treat generalized pustular psoriasis in pediatric patients aged 12 years and older weighing 40 kg or more, Boehringer Ingelheim announced in a press release.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

SAN DIEGO — In children aged 2 to 5 years with atopic dermatitis, roflumilast cream 0.05% significantly improved symptoms compared with vehicle, with improvement seen as early as 1 week after treatment, according to a speaker here.

SAN DIEGO — In this video perspective, Menas Kizoulis, senior director of global scientific engagement at Kenvue, discusses the company’s latest research presented at the American Academy of Dermatology Annual Meeting.